Translated by

RetroSense Terapeutics



RBV Capital


RetroSense Terapeutics is the private biopharmaceutical company developing medicine for treatment of the pigmental retinit and an age makulodistrofiya.

Pigmental retinit – a hereditary incurable degenerative disease of eyes which causes strong deterioration in sight and a blindness; the age makulodistrofiya – group of diseases at which the retina is surprised and is broken the central sight. Pathology of vessels and ischemia of the central area of a retina is the cornerstone of a makulodistrofiya. Both diseases are at the moment incurable, the existing medicines only slow down process of loss of sight, but do not prevent it. From a pigmental retinit in Russia about 50,000 people and about 100,000 – in the CIS suffer. The Retrosense technology is directed to recovery of sight after receptors in a retina died that will allow to return sight to blind and visually impaired people, as in Russia, and around the world. The existing medicines only slow down process of loss of sight because of the pigmental retinit, but do not prevent it, and the medicine RetroSense Therapeutics RTS-001 can become an effective remedy for partial recovery of sight at such patients.


In November, 2015 RBV Capital venture fund together with a pool of the international investors of BlueWater Angels, ExSight Capital and Santen Pharmaceutical Co., Ltd. invested in RetroSense Terapeutics company $ US dollars 6 million in an investment V-round. Earlier $7 million in the A-round, as a result total investment were already invested in the company, received by the company reached $13 million.


RetroSense Therapeutics, portfolio company of the RBV Capital fund created with participation of the capital of RVC is recognized in the summer of 2016 one of the most promising startups the rating of 50 Smartest Companies 2016. The rating annually is formed the Massachusetts Institute of Technology (MIT).

The RetroSense Therapeutics company developing methods of fight against earlier incurable diseases of eyes was selected by editors of MIT Technology Review among 50 companies from around the world which best of all combine the innovative technologies with an effective business model. Having outstripped, including, IBM and Snapchat, RetroSense Therapeutics companies took the 37th place in rating for use of technologies of optogenetics and gene therapy thanks to which combination it is possible to give photosensitivity to cells of a retina of a human eye at the patients suffering from complete or almost total loss of sight because of the pigmental retinit or an age makulodistrofiya.